Bristol-Myers Squibb Co
NYSE:BMY
Intrinsic Value
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. [ Read More ]
The intrinsic value of one
BMY
stock under the Base Case scenario is
84.95
USD.
Compared to the current market price of 59.1 USD,
Bristol-Myers Squibb Co
is
Undervalued by 30%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access Bristol-Myers Squibb Co's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
Fundamental Analysis
Balance Sheet Decomposition
Bristol-Myers Squibb Co
| Current Assets | 28.1B |
| Cash & Short-Term Investments | 8.7B |
| Receivables | 15.1B |
| Other Current Assets | 4.3B |
| Non-Current Assets | 65.4B |
| Long-Term Investments | 2B |
| PP&E | 7.6B |
| Intangibles | 52.5B |
| Other Non-Current Assets | 3.3B |
| Current Liabilities | 20.2B |
| Accounts Payable | 3.1B |
| Accrued Liabilities | 9.3B |
| Short-Term Debt | 606m |
| Other Current Liabilities | 7.2B |
| Non-Current Liabilities | 41.4B |
| Long-Term Debt | 34.7B |
| Other Non-Current Liabilities | 6.7B |
BMY Profitability Score
Profitability Due Diligence
Bristol-Myers Squibb Co's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Bristol-Myers Squibb Co's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
BMY Solvency Score
Solvency Due Diligence
Bristol-Myers Squibb Co's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Bristol-Myers Squibb Co's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BMY Price Targets Summary
Bristol-Myers Squibb Co
According to Wall Street analysts, the average 1-year price target for
BMY
is 74.41 USD
with a low forecast of 56.56 USD and a high forecast of 94.5 USD.
Ownership
BMY Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BMY Price
Bristol-Myers Squibb Co
| Average Annual Return | 3.73% |
| Standard Deviation of Annual Returns | 16.63% |
| Max Drawdown | -31% |
| Market Capitalization | 124B USD |
| Shares Outstanding | 2 100 850 048 |
| Percentage of Shares Shorted | 2.1% |
BMY News
Last Video News
Bristol-Myers Squibb Co
Last Important Events
Bristol-Myers Squibb Co
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Bristol-Myers Squibb Co
Company Profile
Bristol-Myers Squibb Co
Country
Industry
Market Cap
Dividend Yield
Description
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in New York City, New York and currently employs 32,200 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The firm offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. The Company’s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Contact
IPO
Employees
Officers
The intrinsic value of one
BMY
stock under the Base Case scenario is
84.95
USD.
Compared to the current market price of 59.1 USD,
Bristol-Myers Squibb Co
is
Undervalued by 30%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
